Ruben Rose1, Franziska Neumann2, Olaf Grobe2, Thomas Lorentz2, Helmut Fickenscher1, Andi Krumbholz3,4. 1. Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105, Kiel, Germany. 2. Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106, Kiel, Germany. 3. Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105, Kiel, Germany. krumbholz@infmed.uni-kiel.de. 4. Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106, Kiel, Germany. krumbholz@infmed.uni-kiel.de.
Abstract
BACKGROUND: The humoral immune response after primary immunisation with a SARS-CoV-2 vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost (Pfizer/BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody response after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2). METHODS: Sera from 59 vaccinees were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) and virus-neutralising antibodies (VNA) with three IgG assays based on (parts of) the SARS-CoV-2 spike (S)-protein as antigen, an IgG immunoblot (additionally contains the SARS-CoV-2 nucleoprotein (NP) as an antigen), a surrogate neutralisation test (sVNT), and a Vero-cell-based virus-neutralisation test (cVNT) with the B.1.1.7 variant of concern (VOC; alpha) as antigen. Investigation was done before and after heterologous (n = 30 and 42) or homologous booster vaccination (AZD1222/AZD1222, n = 8/9; BNT162b2/BNT162b2, n = 8/8). After the second immunisation, a subgroup of 26 age- and gender-matched sera (AZD1222/mRNA, n = 9; AZD1222/AZD1222, n = 9; BNT162b2/BNT162b2, n = 8) was also tested for VNA against VOC B.1.617.2 (delta) in the cVNT. The strength of IgG binding to separate SARS-CoV-2 antigens was measured by avidity. RESULTS: After the first vaccination, the prevalence of IgG directed against the (trimeric) SARS-CoV-2 S-protein and its receptor binding domain (RBD) varied from 55-95% (AZD1222) to 100% (BNT162b2), depending on the vaccine regimen and the SARS-CoV-2 antigen used. The booster vaccination resulted in 100% seroconversion and the occurrence of highly avid IgG, which is directed against the S-protein subunit 1 and the RBD, as well as VNA against VOC B.1.1.7, while anti-NP IgGs were not detected. The results of the three anti-SARS-CoV-2 IgG tests showed an excellent correlation to the VNA titres against this VOC. The agreement of cVNT and sVNT results was good. However, the sVNT seems to overestimate non- and weak B.1.1.7-neutralising titres. The anti-SARS-CoV-2 IgG concentrations and the B.1.1.7-neutralising titres were significantly higher after heterologous vaccination compared to the homologous AZD1222 scheme. If VOC B.1.617.2 was used as antigen, significantly lower VNA titres were measured in the cVNT, and three (33.3%) vector vaccine recipients had a VNA titre < 1:10. CONCLUSIONS: Heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-SARS-CoV-2 IgG concentrations and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination scheme. Irrespective of the chosen immunisation regime, highly avid IgG antibodies can be detected just 2 weeks after the second vaccine dose indicating the development of a robust humoral immunity. The reduction in the VNA titre against VOC B.1.617.2 observed in the subgroup of 26 individuals is remarkable and confirms the immune escape of the delta variant.
BACKGROUND: The humoral immune response after primary immunisation with a SARS-CoV-2 vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost (Pfizer/BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody response after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2). METHODS: Sera from 59 vaccinees were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) and virus-neutralising antibodies (VNA) with three IgG assays based on (parts of) the SARS-CoV-2 spike (S)-protein as antigen, an IgG immunoblot (additionally contains the SARS-CoV-2 nucleoprotein (NP) as an antigen), a surrogate neutralisation test (sVNT), and a Vero-cell-based virus-neutralisation test (cVNT) with the B.1.1.7 variant of concern (VOC; alpha) as antigen. Investigation was done before and after heterologous (n = 30 and 42) or homologous booster vaccination (AZD1222/AZD1222, n = 8/9; BNT162b2/BNT162b2, n = 8/8). After the second immunisation, a subgroup of 26 age- and gender-matched sera (AZD1222/mRNA, n = 9; AZD1222/AZD1222, n = 9; BNT162b2/BNT162b2, n = 8) was also tested for VNA against VOC B.1.617.2 (delta) in the cVNT. The strength of IgG binding to separate SARS-CoV-2 antigens was measured by avidity. RESULTS: After the first vaccination, the prevalence of IgG directed against the (trimeric) SARS-CoV-2 S-protein and its receptor binding domain (RBD) varied from 55-95% (AZD1222) to 100% (BNT162b2), depending on the vaccine regimen and the SARS-CoV-2 antigen used. The booster vaccination resulted in 100% seroconversion and the occurrence of highly avid IgG, which is directed against the S-protein subunit 1 and the RBD, as well as VNA against VOC B.1.1.7, while anti-NP IgGs were not detected. The results of the three anti-SARS-CoV-2 IgG tests showed an excellent correlation to the VNA titres against this VOC. The agreement of cVNT and sVNT results was good. However, the sVNT seems to overestimate non- and weak B.1.1.7-neutralising titres. The anti-SARS-CoV-2 IgG concentrations and the B.1.1.7-neutralising titres were significantly higher after heterologous vaccination compared to the homologous AZD1222 scheme. If VOC B.1.617.2 was used as antigen, significantly lower VNA titres were measured in the cVNT, and three (33.3%) vector vaccine recipients had a VNA titre < 1:10. CONCLUSIONS: Heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-SARS-CoV-2 IgG concentrations and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination scheme. Irrespective of the chosen immunisation regime, highly avid IgG antibodies can be detected just 2 weeks after the second vaccine dose indicating the development of a robust humoral immunity. The reduction in the VNA titre against VOC B.1.617.2 observed in the subgroup of 26 individuals is remarkable and confirms the immune escape of the delta variant.
Authors: Matthew Frieman; Anthony D Harris; Ramin Sedaghat Herati; Florian Krammer; Alberto Mantovani; Maria Rescigno; Mohammad M Sajadi; Viviana Simon Journal: EBioMedicine Date: 2021-05-26 Impact factor: 8.143
Authors: David Hillus; Tatjana Schwarz; Pinkus Tober-Lau; Kanika Vanshylla; Hana Hastor; Charlotte Thibeault; Stefanie Jentzsch; Elisa T Helbig; Lena J Lippert; Patricia Tscheak; Marie Luisa Schmidt; Johanna Riege; André Solarek; Christof von Kalle; Chantip Dang-Heine; Henning Gruell; Piotr Kopankiewicz; Norbert Suttorp; Christian Drosten; Harald Bias; Joachim Seybold; Florian Klein; Florian Kurth; Victor Max Corman; Leif Erik Sander Journal: Lancet Respir Med Date: 2021-08-13 Impact factor: 30.700
Authors: Emma C Wall; Mary Wu; Ruth Harvey; Gavin Kelly; Scott Warchal; Chelsea Sawyer; Rodney Daniels; Philip Hobson; Emine Hatipoglu; Yenting Ngai; Saira Hussain; Jerome Nicod; Robert Goldstone; Karen Ambrose; Steve Hindmarsh; Rupert Beale; Andrew Riddell; Steve Gamblin; Michael Howell; George Kassiotis; Vincenzo Libri; Bryan Williams; Charles Swanton; Sonia Gandhi; David Lv Bauer Journal: Lancet Date: 2021-06-03 Impact factor: 79.321
Authors: Alberto M Borobia; Antonio J Carcas; Mayte Pérez-Olmeda; Luis Castaño; María Jesús Bertran; Javier García-Pérez; Magdalena Campins; Antonio Portolés; María González-Pérez; María Teresa García Morales; Eunate Arana-Arri; Marta Aldea; Francisco Díez-Fuertes; Inmaculada Fuentes; Ana Ascaso; David Lora; Natale Imaz-Ayo; Lourdes E Barón-Mira; Antonia Agustí; Carla Pérez-Ingidua; Agustín Gómez de la Cámara; José Ramón Arribas; Jordi Ochando; José Alcamí; Cristóbal Belda-Iniesta; Jesús Frías Journal: Lancet Date: 2021-06-25 Impact factor: 79.321
Authors: Xinxue Liu; Robert H Shaw; Arabella S V Stuart; Melanie Greenland; Parvinder K Aley; Nick J Andrews; J Claire Cameron; Sue Charlton; Elizabeth A Clutterbuck; Andrea M Collins; Tanya Dinesh; Anna England; Saul N Faust; Daniela M Ferreira; Adam Finn; Christopher A Green; Bassam Hallis; Paul T Heath; Helen Hill; Teresa Lambe; Rajeka Lazarus; Vincenzo Libri; Fei Long; Yama F Mujadidi; Emma L Plested; Samuel Provstgaard-Morys; Maheshi N Ramasamy; Mary Ramsay; Robert C Read; Hannah Robinson; Nisha Singh; David P J Turner; Paul J Turner; Laura L Walker; Rachel White; Jonathan S Nguyen-Van-Tam; Matthew D Snape Journal: Lancet Date: 2021-08-06 Impact factor: 79.321
Authors: Verena Klemis; David Schub; Tina Schmidt; Janine Mihm; Franziska Hielscher; Stefanie Marx; Amina Abu-Omar; Laura Ziegler; Candida Guckelmus; Rebecca Urschel; Sophie Schneitler; Sören L Becker; Barbara C Gärtner; Urban Sester; Martina Sester Journal: Nat Med Date: 2021-07-26 Impact factor: 53.440
Authors: Robert Daniel Heinrich Markewitz; David Juhl; Daniela Pauli; Siegfried Görg; Ralf Junker; Jan Rupp; Sarah Engel; Katja Steinhagen; Victor Herbst; Dorinja Zapf; Christina Krüger; Christian Brockmann; Frank Leypoldt; Justina Dargvainiene; Benjamin Schomburg; Shahpour Reza Sharifzadeh; Lukas Salek Nejad; Klaus-Peter Wandinger; Malte Ziemann Journal: Vaccines (Basel) Date: 2022-04-20
Authors: Ana Tajuelo; Octavio Carretero; Estéfani García-Ríos; Mireia López-Siles; Olga Cano; Mónica Vázquez; Vicente Más; Isabel Rodríguez-Goncer; Antonio Lalueza; Francisco López-Medrano; Rafael San Juan; Mario Fernández-Ruiz; José Mᵃ Aguado; Michael J McConnell; Pilar Pérez-Romero Journal: Front Immunol Date: 2022-04-25 Impact factor: 8.786